As part of our processes to monitor and address risks, during the first quarter, we entered into an extension of our interest rate hedge, providing stability to our interest rate risk through September 2026. Prior to any proceeds from the pending community living divestiture, quarterly interest expense is still expected to be approximately $43,000,000 per quarter, including approximately $1,200,000 of interest expense related to the TEU instrument. Turning to our guidance for 2025, we are increasing our expectations for total revenue and adjusted EBITDA that was provided in March, which excludes the Community Living business. Total revenue is expected to be in the range of $12,000,000,000 to 12,500,000,000.0 including pharmacy solutions revenue of $10,550,000,000 to $11,000,000,000 and provider services revenue of $1,450,000,000 to $1,500,000,000 This revenue range reflects 19.1% to 24.1% growth over full year 2024, excluding community living in both years. Total adjusted EBITDA is expected to be in the range of $570,000,000 to $585,000,000 for full year 2025.